Simple immunoturbidimetric method for determining urinary albumin at low concentrations using Cobas-Bio centrifugal analyser.

Kearney, E.; Mount, J N; Watts, G F; Slavin, B; Kind, P. R. N.

doi:10.1136/jcp.40.4.465

Cited by 68 publications

(47 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The between-batch coefficient of variation (CV) of this assay was 3.8%. Urinary albumin excretion rate (AER) was determined by an immunoturbimetric method using goat anti-human albumin antiserum and human albumin standards on a timed 24-h urine collection, after exclusion of urinary tract infection (13). Microalbuminuria was defined as a urinary AER of 20-200 µg/min.…”

Section: Assaysmentioning

confidence: 99%

Relationship Between Plasma Sialic Acid Concentration and Microvascular and Macrovascular Complications in Type 1 Diabetes

Pj³

et al. 2001

Diabetes Care

View full text Add to dashboard Cite

The APPENDIX section contains a complete list of centers that participated in the EURODIAB IDDM Complications Study.Abbreviations: AER, albumin excretion rate; CHD, coronary heart disease; CV, coefficient of variation. A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances. Relationship Between Plasma Sialic Acid Concentration and Microvascular and Macrovascular Complications in Type 1 DiabetesThe EURODIAB Complications StudyOBJECTIVE -To test the hypothesis that an increased plasma concentration of sialic acid, a marker of the acute-phase response, is related to the presence of diabetic micro-and macrovascular complications in type 1 diabetes. RESEARCH DESIGN AND METHODS -We investigated the relationship betweenplasma sialic acid concentration and nephropathy, retinopathy, neuropathy, and coronary heart disease (CHD) in a cross-sectional survey of 1,369 people with type 1 diabetes. Subjects were participants in the EURODIAB IDDM Complications Study, which involved 31 centers in 16 European countries.RESULTS -There was a significantly increasing trend of plasma sialic acid with severity of retinopathy (P Ͻ 0.001 in men) and with degree of urinary albumin excretion (P Ͻ 0.001 men, P Ͻ 0.01 women). Plasma sialic acid correlated with increasing plasma creatinine concentration (P Ͻ 0.009 men, P Ͻ 0.0002 women), and men with neuropathy had a higher plasma sialic acid concentration than those without (P Ͻ 0.006). There was no significant correlation between plasma sialic acid and CHD in either sex. Elevated plasma sialic acid concentrations were also associated with several risk factors for diabetic vascular disease: diabetes duration, HbA 1c , plasma triglyceride and cholesterol concentrations, waist-to-hip ratio, hypertension and smoking (in men), and low physical exercise (in women). In multiple logistic regression analysis, plasma sialic acid was independently related to proliferative retinopathy and urinary albumin excretion rate in men.CONCLUSIONS -We conclude that an elevated plasma sialic concentration is strongly related to the presence of microvascular complications in type 1 diabetes, especially retinopathy and nephropathy. Further study of acute-phase response markers and mediators as indicators or predictors of diabetic microvascular complications is therefore justified.

show abstract

Section: Assaysmentioning

confidence: 99%

Relationship Between Plasma Sialic Acid Concentration and Microvascular and Macrovascular Complications in Type 1 Diabetes

Pj³

et al. 2001

Diabetes Care

View full text Add to dashboard Cite

show abstract

“…Samples were tested for infection by dipstick (Nephur test) and, if positive, the collections were discarded and a fresh collection advised after any infection had been treated. If the dipstick was negative, aliquots were frozen and sent to London for analysis of urinary albumin, using an immunoturbidimetric method [4] with goat anti-human albumin antisera (Sanofi Diagnostics Pasteur, Minn., USA) and human serum albumin standards (ORHA 20/21 grade HSA; Behring Diagnostics, Hoechst UK, Hounslow UK). The same laboratory was used for baseline 60 µg/min (n=63) and 26.4% had values between 61 and 200 µg/min (n=93) ( Table 1).…”

Section: Methodsmentioning

confidence: 99%

Factors associated with progression to macroalbuminuria in microalbuminuric Type 1 diabetic patients: the EURODIAB Prospective Complications Study

et al. 2004

View full text Add to dashboard Cite

Aims/hypothesis. Type 1 diabetic patients who develop microalbuminuria are clearly disadvantaged in terms of their risk of morbidity and mortality from renal and cardiovascular diseases. It is therefore important to identify potential factors that can predict progression to macroalbuminuria. Methods. This is a 7-year follow-up study of 352 microalbuminuric Type 1 diabetic patients from 31 European centres. Risk factors at baseline were compared in patients who progressed to macroalbuminuria and in patients who remained microalbuminuric or reverted to normoalbuminuria. Risk factors and albumin excretion rate (AER) were measured centrally. Results. Over 7.3 years, 13.9% of the microalbuminuric patients progressed to macroalbuminuria, 35.5% remained microalbuminuric and 50.6% reverted to normoalbuminuria. Independent baseline risk factors for progression to macroalbuminuria were HbA 1 c (7.9% vs 6.8%, p=0.004), AER (64.4 vs 44.9 µg/min, p=0.0001) and-after adjusting for diabetes duration, HbA 1 c and AER-body weight (72 vs 67 kg, p=0.05). Independent factors associated with regression to normoalbuminuria were diabetes duration (15 vs 18 years, p=0.004), AER (37.2 vs 44.9 µg/min, p=0.0001) andafter adjusting for diabetes duration, HbA 1 c and AER-waist-to-hip ratio (0.83 vs 0.86, p=0.05) and incidence of peripheral neuropathy at baseline (24% vs 38%, p=0.001). Blood pressure and smoking did not emerge as risk factors at baseline for the outcome of microalbuminuria. Conclusions/interpretation. A significant fraction of microalbuminuric Type 1 diabetic patients will progress to overt proteinuria. Patients with higher AER values, sub-optimal metabolic control, excess body fat and peripheral neuropathy may carry a particularly high risk of clinical nephropathy requiring aggressive therapeutic intervention.

show abstract

“…Urinary albumin was measured in a single laboratory by an immunoturbidimetric method (Sanofi Diagnostics Pasteur, Minneapolis, Minn., USA) [28]. Albumin excretion rate was categorised as normoalbuminuria at 20 µg/min or less, microalbuminuria between 20 and 200 µg/min and macroalbuminuria at 200 µg/min or more.…”

Section: Methodsmentioning

confidence: 99%

Trends in hypertension management in Type I diabetes across Europe, 1989/1990 – 1997/1999

et al. 2002

View full text Add to dashboard Cite

Aims/hypothesis Our aim was to examine the change in the management of hypertension in patients with Type I (insulin-dependent) diabetes mellitus in Europe, between 1989Europe, between -1990Europe, between and 1997Europe, between -1999.Methods Seven-year changes in hypertension treatment and control (defined as blood pressure <130/85 mmHg) were examined in a large sample of Type I diabetic patients recruited from 26 centres involved in the EURODIAB Prospective Complications Study. Hypertension was defined as a systolic and/or diastolic blood pressure greater than 140 and/or 90 mmHg respectively, and/or use of blood pressure lowering drugs. 1Results Of 1866 Type I diabetic patients, 412 had hypertension at baseline and 631 at follow-up.A greater proportion of hypertensive patients were treated at follow-up (69% vs 40%, p<0.0001), which persisted after adjustment for age or centre. Of those who were treated, a modest increase in the proportion of those controlled for hypertension was found (41% vs 32%, p=0.048), which disappeared after adjustment for age. Among hypertensive patients with albuminuria, the proportions treated also increased, from 35% to 76% (p<0.0001) in microalbuminuric and 64% to 95% (p<0.0001) in macroalbuminuric patients. Control of hypertension in albuminuric patients did not change significantly and was below 50%. The use of more than one anti-hypertensive drug increased over a 7-year period, from 19% to 33% (p<0.0001), and a marked increase was shown in the proportion of those taking an ACE inhibitor (from 57% to 82%, p<0.0001). Conclusion/interpretationThe management of hypertension in Type I diabetic patients acrossEurope has improved over a 7-year follow-up period. Optimal levels of blood pressure treatment and optimal levels of control have not yet been achieved.Keywords Hypertension · Type I diabetes mellitus · albuminuria · control · blood pressure · treatment Abbreviations CCB Calcium channel blockerAn erratum to this article can be found at http://dx.doi.org/10.1007/s00125-003-1210-9In Type I (insulin-dependent) diabetes mellitus, raised blood pressure has been shown to be related to an increased risk of retinopathy [1,2,3], and cardiovascular disease [4,5] in several prospective studies independent of other risk factors. It is estimated that 30 to 75% of diabetic complications can be attributed to hypertension, which is twice as common in diabetic patients than in non-diabeticSeveral BP lowering trials have shown a reduction in microvascular and macrovascular complications in patients with Type II (non-insulin-dependent) diabetes mellitus [7,8]. Other recent trials have shown that, independent from BP lowering effects, the progression of diabetic nephropathy can be reduced by angiotensin II receptor blockers in Type II diabetic patients with hypertension and albuminuria [9,10,11]. In Type I diabetes, the progression of retinopathy [12]

show abstract

Simple immunoturbidimetric method for determining urinary albumin at low concentrations using Cobas-Bio centrifugal analyser.

Cited by 68 publications

References 19 publications

Relationship Between Plasma Sialic Acid Concentration and Microvascular and Macrovascular Complications in Type 1 Diabetes

Relationship Between Plasma Sialic Acid Concentration and Microvascular and Macrovascular Complications in Type 1 Diabetes

Factors associated with progression to macroalbuminuria in microalbuminuric Type 1 diabetic patients: the EURODIAB Prospective Complications Study

Trends in hypertension management in Type I diabetes across Europe, 1989/1990 – 1997/1999

Contact Info

Product

Resources

About